Table 1.

The FDA Drug Label for Capecitabine: Warning DPD Deficiency (2020)

PhenotypeCapecitabine
DPD deficiencyIncreased risk of severe or fatal adverse reactions in individuals with low or absent dihydropyrimidine dehydrogenase (DPD) activity.
Withhold or permanently discontinue capecitabine tablets in individuals with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of (DPD) activity.
No capecitabine dose has been proven safe in individuals with absent DPD activity.

Please see Therapeutic Recommendations based on Genotype for more information from FDA. This table is adapted from (1).

From: Capecitabine Therapy and DPYD Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.